Alliance Global Partners Initiates Coverage on GeoVax Labs (NASDAQ:GOVX)

Alliance Global Partners started coverage on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $15.00 price target on the stock. Alliance Global Partners’ price objective suggests a potential upside of 361.54% from the company’s current price.

Other research analysts also recently issued reports about the company. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Roth Mkm initiated coverage on shares of GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price target on the stock. Noble Financial raised their price target on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Monday, August 12th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $13.25.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $3.25 on Monday. The business has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $2.58. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.